Michael Hocko, MD
Infectious Disease · Buffalo, NYNPI 1043271646
Payments from drug & device makers
Across 46 payments — averaging $17.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$311
- Melinta Therapeutics, LLC$144
- Paratek Pharmaceuticals, Inc.$115
- Astellas Pharma US Inc$80
- Insmed, Inc.$77
- Merck$46
- plus $40 from 1 others
What the payments were for
- Food & beverage$66782%
- Education$14518%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 18 | $311 |
| Melinta Therapeutics, LLC | 9 | $144 |
| Paratek Pharmaceuticals, Inc. | 7 | $115 |
| Astellas Pharma US Inc | 2 | $80 |
| Insmed, Inc. | 5 | $77 |
| Merck | 3 | $46 |
| Dexcom, Inc. | 2 | $40 |
How this compares
$812 in reported general payments places this provider in the 60th percentile of 799 infectious disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 65 | $48,421 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 56 | $9,956 |
| ErtapenemErtapenem Sodium | 15 | $6,799 |
| Meropenem | 24 | $5,994 |
| Vancomycin Hcl | 52 | $5,608 |
| Amoxicillin-Clavulanate Pot ErAmoxicillin/Potassium Clav | 12 | $3,842 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 123 | $3,199 |
| Cefdinir | 99 | $2,062 |
| Doxycycline Hyclate | 113 | $1,771 |
| Cephalexin | 133 | $1,750 |
| Cefepime Hcl | 13 | $1,421 |
| Cefazolin Sodium | 36 | $1,194 |
| CholestyramineCholestyramine (With Sugar) | 17 | $1,111 |
| CeftriaxoneCeftriaxone Sodium | 24 | $1,025 |
| Levofloxacin | 108 | $618 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Buffalo
- Alyssa ShonBuffalo$307K
- Wafaa El SadrNew York$119.1M
- Judith AbergNew York$14.8M
- Stephen ThomasSyracuse$6.2M
- Edward WalshRochester$3.9M
- Magdalena SobieszczykNew York$2.9M
- Kristen MarksNew York$2.8M
- Genovefa PapanicolaouNew York$2.7M
- Catherine SmallValhalla$2.7M
- Ann FalseyRochester$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.